GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Dr. Rossi is Professor and Chair of the Division of Molecular Biology, Beckman Research Institute of the City of Hope, and Dean, Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope. Dr. Rossi received his doctoral training in genetics under Dr. Claire Berg at the University of Connecticut in Storrs and postdoctoral training in molecular genetics under Dr. Arthur Landy at Brown University. In the 1980s and 1990s his research focused on the mechanism of action and clinical applications of catalytic RNAs, or ribozymes. His group was the first to demonstrate that hammerhead ribozymes could be used for inhibition of HIV replication. This research program led to two clinical trials in which ribozyme genes have been transduced into hematopoietic stem cells for autologous transplant in HIV infected individuals. He is the recipient of an NIH Merit award for his work on ribozymes and HIV. Work in the laboratory continues to focus upon RNA based therapeutics, with recent emphasis on function and applications of expressed short hairpin RNAs for therapeutic treatment of HIV and cancers. This research has led to a planned clinical trial for RNAi based therapy of HIV infection in a gene therapy setting. He has published over 200 peer reviewed articles and numerous reviews and commentaries on RNAi based therapeutics.


Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?